Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03677596
Title A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients
Recruitment Active, not recruiting
Gender both
Phase FDA approved
Variant Requirements No
Sponsors Pfizer

lymphoblastic lymphoma

B-cell acute lymphoblastic leukemia


Inotuzumab ozogamicin

Age Groups: adult | senior
Covered Countries USA | ESP

No variant requirements are available.